$INCY (INCYTE) — 8-K: Incyte cancels planned Phase 3 MAESTRA-3 study of INCB123667 in ovarian cancer

Incyte will not proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, its selective CDK2 inhibitor, combined with bevacizumab as first-line maintenance therapy in ovarian cancer, which had been expected to begin in the fourth quarter of 2026. The decision was based on prioritization of the clinical development portfolio and was not based on any safety or efficacy findings from the INCB123667 clinical program. Incyte does not expect the determination to affect its financial guidance or previously disclosed long-term outlook.

Incyte will not proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, its selective CDK2 inhibitor, combined with bevacizumab as first-line maintenance therapy in ovarian cancer, whi